HK1143559A1 - Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide - Google Patents

Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide

Info

Publication number
HK1143559A1
HK1143559A1 HK10110208.5A HK10110208A HK1143559A1 HK 1143559 A1 HK1143559 A1 HK 1143559A1 HK 10110208 A HK10110208 A HK 10110208A HK 1143559 A1 HK1143559 A1 HK 1143559A1
Authority
HK
Hong Kong
Prior art keywords
napthalenamine
dichlorophenyl
tetrahydro
formamide
trans
Prior art date
Application number
HK10110208.5A
Other languages
English (en)
Inventor
Thomas P Jerussi
Qun Kevin Fang
Mark Currie
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of HK1143559A1 publication Critical patent/HK1143559A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HK10110208.5A 2002-09-16 2010-10-29 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide HK1143559A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41130402P 2002-09-16 2002-09-16
US41130502P 2002-09-16 2002-09-16

Publications (1)

Publication Number Publication Date
HK1143559A1 true HK1143559A1 (en) 2011-01-07

Family

ID=31998027

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10110208.5A HK1143559A1 (en) 2002-09-16 2010-10-29 Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide

Country Status (16)

Country Link
US (6) US7087785B2 (pt)
EP (1) EP1542961B1 (pt)
JP (1) JP4610336B2 (pt)
KR (2) KR101067045B1 (pt)
CN (1) CN101712626B (pt)
AU (1) AU2003272460B2 (pt)
BR (1) BRPI0314377B8 (pt)
CA (1) CA2498152C (pt)
DK (1) DK1542961T3 (pt)
ES (1) ES2431519T3 (pt)
HK (1) HK1143559A1 (pt)
IL (1) IL167319A (pt)
MX (1) MXPA05002700A (pt)
NZ (1) NZ538741A (pt)
PT (1) PT1542961E (pt)
WO (1) WO2004024669A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05002700A (es) * 2002-09-16 2005-09-08 Sepracor Inc Tratamiento de trastornos del sistema nervioso central con trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1-naftalenamina y su formamida.
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
EP1691811B1 (en) * 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
PL380887A1 (pl) * 2003-12-29 2007-04-02 Sepracor Inc. Pirolowe i pirazolowe inhibitory DAAO
US20060199739A1 (en) * 2005-03-02 2006-09-07 Olav Messerschmidt Limonene-containing herbicide compositions, herbicide concentrate formulations and methods for making and using same
EP1904066B1 (en) * 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. COMBINATIONS OF ESZOPICLONE AND TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE, for treating MENOPAUSE, perimenopause AND COGNITIVE DISORDERS
JP2009522721A (ja) * 2005-12-29 2009-06-11 ユーティーシー パワー コーポレイション ガス輸送式燃料電池冷媒の循環
US20070203111A1 (en) 2006-01-06 2007-08-30 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
CN104276955A (zh) 2006-01-06 2015-01-14 赛诺维信制药公司 基于四氢萘酮的单胺再摄取抑制剂
AU2013211500B2 (en) * 2006-03-31 2016-08-04 Sepracor Inc Preparation of chiral amides and amines
ES2555315T3 (es) * 2006-03-31 2015-12-30 Sunovion Pharmaceuticals Inc. Preparación de amidas y aminas quirales
WO2007143267A2 (en) * 2006-05-31 2007-12-13 Sepracor Inc. Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
KR101329658B1 (ko) * 2006-09-25 2013-11-14 아처 다니엘 미드랜드 캄파니 초흡수성 표면처리된 카르복시알킬화 다당류 및 그 제조방법
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
US8138377B2 (en) * 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
CA2676432A1 (en) * 2007-01-18 2008-07-24 Sepracor, Inc. Inhibitors of d-amino acid oxidase
MX2009012685A (es) 2007-05-31 2009-12-14 Sepracor Inc Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina.
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
JP2012526832A (ja) * 2009-05-13 2012-11-01 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリン及びセロトニン受容体１ａ作動剤／拮抗剤を含む組成物及びその使用
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
MX339619B (es) * 2009-12-04 2016-06-02 Sunovion Pharmaceuticals Inc Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
WO2012158892A2 (en) 2011-05-19 2012-11-22 Bruce Roseman A method of treating apraxia of speech in children
US20140163070A1 (en) 2012-05-17 2014-06-12 Bruce Roseman Treatment for cerebral palsy impaired speech in children
US9220712B2 (en) 2011-05-19 2015-12-29 Gilrose Pharmaceuticals, Llc Pharmaceutical intervention and method for treating an apraxia of speech in children
US9682073B2 (en) 2011-05-19 2017-06-20 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder gait and limb impairments treatment
US8883815B2 (en) 2011-05-19 2014-11-11 Gilrose Pharmaceuticals, Llc Treatment for cerebral palsy impaired speech in children
US10085414B2 (en) 2011-05-19 2018-10-02 Gilrose Pharmaceuticals, Llc Pre-frontal cortex processing disorder speech, gait and limb impairments treatment
WO2015175514A1 (en) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Methods and compositions of dasotraline for treatment of adhd
US10076503B2 (en) 2014-05-13 2018-09-18 Sunovion Pharmaceuticals Inc. Dosage of dasotraline and method for treatment of ADHD
WO2016046669A2 (en) * 2014-09-27 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of depression and neurological diseases
WO2019143920A1 (en) 2018-01-19 2019-07-25 Sunovion Pharmaceuticals Inc. Oral dosage forms
US20210386689A1 (en) 2018-10-31 2021-12-16 Sunovion Pharmaceuticals Inc. Methods of treating central nervous system disorders
EP3800178A1 (en) 2019-10-01 2021-04-07 Moehs Ibérica, S.L. Preparation of enamide intermediate for the synthesis of dasotraline

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556676A (en) * 1979-11-01 1985-12-03 Pfizer Inc. Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS59497B2 (ja) * 1979-11-01 1984-01-07 フアイザ−・インコ−ポレ−テツド トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5778986A (en) * 1997-08-05 1998-07-14 Davis; Floyd A. Device to remove divots
US6245782B1 (en) * 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
MXPA05002700A (es) * 2002-09-16 2005-09-08 Sepracor Inc Tratamiento de trastornos del sistema nervioso central con trans 4-(3,4-diclorofenil)-1,2,3,4-tetrahidro-1-naftalenamina y su formamida.

Also Published As

Publication number Publication date
BR0314377A (pt) 2005-07-19
US20060216799A1 (en) 2006-09-28
US20040092605A1 (en) 2004-05-13
US20090292026A1 (en) 2009-11-26
EP1542961A1 (en) 2005-06-22
KR20050084552A (ko) 2005-08-26
NZ538741A (en) 2007-01-26
CN101712626B (zh) 2013-11-20
AU2003272460B2 (en) 2009-12-17
DK1542961T3 (da) 2013-11-04
CA2498152A1 (en) 2004-03-25
US7790772B2 (en) 2010-09-07
CA2498152C (en) 2012-01-10
CN101712626A (zh) 2010-05-26
BRPI0314377B8 (pt) 2021-05-25
JP4610336B2 (ja) 2011-01-12
US20080280993A1 (en) 2008-11-13
KR20110091043A (ko) 2011-08-10
AU2003272460A2 (en) 2004-04-30
MXPA05002700A (es) 2005-09-08
US7087785B2 (en) 2006-08-08
US7589237B2 (en) 2009-09-15
JP2005539068A (ja) 2005-12-22
EP1542961B1 (en) 2013-09-11
US20060014982A1 (en) 2006-01-19
ES2431519T3 (es) 2013-11-26
BRPI0314377B1 (pt) 2020-11-24
PT1542961E (pt) 2013-11-05
WO2004024669A1 (en) 2004-03-25
IL167319A (en) 2013-10-31
KR101067045B1 (ko) 2011-09-22
US20060128993A1 (en) 2006-06-15
KR101165549B1 (ko) 2012-07-19
US7423179B2 (en) 2008-09-09
US7105699B2 (en) 2006-09-12
AU2003272460A1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
HK1143559A1 (en) Treatment of cns disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydro-1-napthalenamine and its formamide
NO20034996D0 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme, type II diabetesog CNS-forstyrrelser
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
IL158631A0 (en) 4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AP2334A (en) Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders.
HK1070361A1 (en) 5-sulphanyl-4h-1,2,4-triazole derivatives and their use to treat disorders associated with somatostatine
PL370163A1 (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same
ZA200507806B (en) 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
IL165051A0 (en) New compounds useful for the treatment of obesity,type II diabetes and cns disorders
PL367782A1 (en) Arylamines for the treatment of conditions associated with gsk-3
HK1077732B (zh) 提升機構以及結合有該提升機構的護理設備
HK1121463A1 (en) Treatment of tnf alpha related disorders tnf
PL1708790T3 (pl) Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
PL368130A1 (en) 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune diseases
NO20052699D0 (no) 4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
EP1499309A4 (en) PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
NO20034232D0 (no) Anvendelse av glukokortikoid-reseptor-spesifikke antagonister ved behandling av stresslidelser
IL158704A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1041880A1 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders.
IL195441A0 (en) Use of trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthaleneamine and its formamide in the preparation of medicaments for the treatment of pain disorders
EP1379236A4 (en) TREATMENT OF TICS, TREMORS AND RELATED DISORDERS
IL158703A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL1786759T3 (pl) Nowe pochodne 3,5-seko-4-norcholestanowe i ich zastosowanie
GB0128674D0 (en) Treatment of sleep disorders and the like
IL158632A0 (en) 4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220911